Skip to Content
Regeneron’s anti-coronavirus cocktail REGEN-COV was provisionally approved in November 2020 to treat COVID-19 symptoms, and may also reduce its spread. But to develop the important therapy, the biotechnology and pharmaceuticals firm had to keep its own researchers and other staff safe as one of the first U.S. hotspots exploded just miles from its Tarrytown, N.Y., headquarters. The company sent nonessential workers home while implementing safety measures in its research labs. By spring of 2020 Regeneron was providing regular COVID testing for employees, and indefinite paid leave for those infected to recover and quarantine. The firm donated coronavirus-testing components to its home state, with hundreds of staff voluntarily working overtime and weekends to produce them. Regeneron also rolled out a new five-year responsibility strategy organized around stakeholders, including new diversity and inclusion measures after the summer’s wave of protests against anti-Black police brutality. Says one employee: “As an African American male, it’s nice to know that I work for a company that really puts its money where its mouth is regarding making changes in underserved communities.”
Courtesy of Regeneron
Lists ranking Regeneron Pharmaceuticals
Fortune 500 - 2021This year’s Fortune 500 marks the 67th running of ...READ MOREview in list
100 Best Companies to Work For - 2021Our 2021 list of the 100 best companies to work fo...READ MOREview in list
100 Fastest-Growing Companies - 2020Collectively, the ranked companies produced a thre...READ MOREview in list
Change the World - 2020As we face unprecedented collective challenges, co...READ MOREview in list